Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab in Nasopharyngeal Carcinoma
NCT02759250Phase 1Completed
- Sponsor
- argenx
- Start
- Feb 2015
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cusatuzumab in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by argenx. Primary endpoint: Incidence and grading of Adverse Events. Started Feb 2015; status: completed.
02
Drugs
cusatuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02759250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759250.